Immunosuppressive Agents and Metabolic Factors of Cardiovascular Risk in Renal Transplant Recipients

Transplantation Proceedings

Volumn 41, Issue 4, 2009, Pages 1178-1182

  Sessa, A ^a   Esposito, A ^a   Giliberti, A ^a   Iavicoli, G ^a   Costa, C ^b   Bergallo, M ^b   Lettieri, E ^a   Rossano, R ^a   Capuano, M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SCDU Virologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; IMMUNOSUPPRESSIVE AGENT; INSULIN; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERURICEMIA; INSULIN RESISTANCE; KIDNEY GRAFT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; METABOLISM; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; RISK REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; HYPERLIPIDEMIAS; KIDNEY TRANSPLANTATION; MIDDLE AGED;

CALCINEURIN INHIBITORS; CARDIOVASCULAR DISEASES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; EVEROLIMUS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; HYPERURICEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPOPROTEINS, HDL; MIDDLE AGED; RISK FACTORS; SIROLIMUS; TACROLIMUS; TRANSPLANT RECIPIENTS;

EID: 65649094514     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.02.045     Document Type: Article

References (45)

1. Bonucchi D., Malaguti V., Ravera F., et al. La prevenzione del rischio cardiovascolare (RCV) nel follow-up del trapianto renale. Trapianti X (2006) 101
2. Sanak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease. Hypertension 42 (2003) 1050
3. USRD 2005 Annual Data Report. Am J Kidney Dis 1 suppl 1 (2006) S152
4. Rigatto C. Clinical epidemiology of cardiac disease in renal transplant recipients. Semin Dial 16 (2003) 106
5. Cecka J.M. The OPTN/UNOS renal transplant registry. In: Cecka J.M., and Terasaki P.I. (Eds). Clinical Transplants 2003 (2003), UCLA, Los Angeles, Calif 1
6. Lindholm A., Albrechtsen D., Frödin L., et al. Ischemic heart disease. Major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 60 (1995) 451
7. Hopkins P.A., and Williams R.R. A survey of 246 suggested coronary risk factors. Atherosclerosis 40 (1981) 1
8. Parvanova A., Trevisan R., Iliev I.P., et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 55 (2006) 1456
9. Parvanova A., Iliev I., et al. Insulin resistance and proliferative retinopathy. J Clin Endocrinol Metab 89 (2004) 4371
10. Stallone G., Infante B., Schena A., et al. II rischio cardiovascolare nel paziente con trapianto renale. G Itali Nefrol 2 (2004) 144
11. Weir M.R. Impact of immunosuppressive regimens on post-transplant diabetes mellitus. Transplant Proc 33 suppl 5A (2001) 23S
12. Jindal R.M. Post transplant diabetes mellitus. A review. Transplantation 58 (1994) 1289
13. Tyden G., Bolinder J., Solders G., et al. Improved survival in patients with insulin-dependent diabetes mellitus and end stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation. Transplantation 67 (1999) 645
14. Opelz G., Wujciak T., and Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 53 (1998) 217
15. Chueh S.C., and Kahan B.D. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosoppressive regimen: incidence, risk factors, progression and prognosis. Transplantation 76 (2003) 375
16. Satterhwaite R., Aswad S., Sunga V., et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 65 (1998) 446
17. Bosmans J.L., Holvoet P., Dauwe S.E., et al. Oxidative modification of low-density lipoproteins and the outcome of renal allograft at 1 years. Kidney Int 59 (2001) 2346
18. Kobashigawa J.A., and Kasike B.L. Hyperlipidemia in solid organ transplantation. Transplantation 63 (1997) 331
19. Fellstrom B., Holdaas H., and Jardine A. Cardiovascular disease in renal transplantation: management by statins. Transplant Rev 18 (2004) 122
20. Morrisett J.D., Abdel-Fattah G., and Kahan B.D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 35 (2003) 143S
21. Kniepeiss D., Iberer F., Schaffellner S., et al. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transplant 18 (2004) 642
22. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115
23. Ridker P. High sensitivity C-reactive protein. Circulation 103 (2001) 1813
24. Ridker P.M., Rifai N., Buring J.E., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557
25. Ducloux D., Kazory A., and Chalopin J.M. Post transplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 79 (2005) 438
26. Frishman W.H. Biologic markers as predictors of cardiovascular disease. Am J Med 104 (1998) S18
27. Friedman A.N., Rosenberg I.H., Selhub J., et al. Hyperhomocysteinemia in renal transplant recipients. Am J Transplant 2 (2002) 308
28. Abdelfatah A., Ducloux D., Toubin G., et al. Treatment of hyperhomocysteinemia with folic acid reduces oxidative stress in renal transplant recipient. Transplantation 73 (2002) 663
29. Arnadottir M., Hultberg B., Vladov V., et al. Hyperhomocysteinemia in cyclosporine treated renal transplant recipients. Transplantation 61 (1996) 509
30. Arnadottir M., Hultberg B., Walberg J., et al. Serum total homocysteine concentration before and after renal transplantation. Kidney Int 54 (1998) 1380
31. Cole D.E., Ross H.J., Evroski J., et al. Correlation between total homocysteine and cyclosporine concentration in cardiac transplantation recipients. Clin Chem 44 (1998) 2307
32. Fernandez-Miranda C., Gomez P., Diaz-Rubio P., et al. Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. Clin Transplant 14 (2000) 110
33. Solez K. International standardization of criteria for histologic diagnosis of chronic rejection in renal allograft. Clin Transplant 8 (1994) 345
34. Vanrenterghem Y., Ponticelli C., Morales J.M., et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 3 (2003) 835
35. Rigatto C., Parfrey P., Foley R., et al. Congestive heart failure in renal transplant recipients. J Am Soc Nephrol 13 (2002) 1084
36. Campise M., Bamonti F., Novembrino C., et al. Oxidative stress in kidney transplant patients. Transplantation 76 (2003) 1474
37. Qunibi W.Y., Barri Y., Devol E., et al. Factor predictive of post transplant erythrocytosis. Kidney Int 40 (1991) 1153
38. Abate N. Obesity as a risk factor for cardiovascular disease. Am J Med 107 suppl 2A (1999) 125
39. Yan L.L., Daviglus M.L., Liu K., et al. Midlife body mass index and hospitalization and mortality in older age. JAMA 295 (2006) 190
40. Erdogan D., Gullu H., Caliskan M., et al. Relationship of serum uric acid to measure endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 59 (2005) 1276
41. Fang J., and Alderman M.H. Serum uric acid cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA 283 (2000) 2404
42. Viazzi F., Leoncini G., Ratto E., et al. Mild hyperuricemia and sub-clinical renal damage in untreated primary hypertension. Am J Hypertens 20 (2007) 1276
43. Mazzali M., Kanellis J., Han I., et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282 (2002) F991
44. Ducloux D., Fournier V., Rebibou J.N., et al. Hyperhomocysteinemia in renal transplant recipients with and without cyclosporine. Clin Nephrol 49 (1998) 232
45. Andres V., Castro C., and Campistol J.M. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. Nephrol Dial Transplant 21 S3 (2006) iii14